Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Vertex presents new voltage-gated sodium channel inhibitors with analgesic activity

May 11, 2009

Analgesic efficacy seen with tanezumab in chronic low back pain patients

May 11, 2009

Abbott describes novel cannabinoid CB2 receptor ligands as analgesics

May 11, 2009

Meta-analysis data suggest possible effectiveness of levetiracetam in status epilepticus

May 11, 2009

Capsaicin does not impair neurologic function in postherpetic neuralgia patients

May 11, 2009

Korea Research Institute of Chemical Technology describes novel inhibitors of ischemic cell death

May 8, 2009

D-Pharm submits IND and SPA to FDA for phase III trial of DP-b99 in acute stroke

May 8, 2009

AcelRx commences phase II clinical trial of ARX-01 Sufentanil NanoTab PCA System

May 8, 2009

Merck initiates phase III SETTLE trial of safinamide in Parkinson's disease

May 8, 2009

Novel compounds for the treatment of pain discovered by Daiichi Sankyo

May 8, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
GSK’s newly acquired Jideytro wins FDA nod in NSCLC
BioWorld
About a week after closing its $10.6 billion acquisition of Nuvalent Inc., GSK plc has reaped the first reward, announcing U.S. FDA approval of zidesamtinib in...